Printer Friendly

Mylan unveils generic Suboxone Sublingual Film for treating opioid dependence.

M2 PHARMA-February 25, 2019-Mylan unveils generic Suboxone Sublingual Film for treating opioid dependence

(C)2019 M2 COMMUNICATIONS

Pharmaceutical company Mylan NV (NASDAQ:MYL) revealed on Friday the availability of Buprenorphine and Naloxone Sublingual Film in 8 mg/2 mg and 12 mg/3 mg in the US.

The company added that Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg is the generic version of Indivior's Suboxone Sublingual Film.

According to the company, the US Food and Drug Administration (FDA) approved Buprenorphine and Naloxone Sublingual Film is indicated for the treatment of opioid dependence under a complete treatment plan that includes counselling and psycho-social support. Its prescription is limited to healthcare providers who meet certain qualifying requirements including notification to Department of Health and Human services of their intent to prescribe this product.

For the 12 months ending 31 December 2018, the US sales for the company's Buprenorphine and Naloxone Sublingual Film in 8 mg/2 mg and 12 mg/3 mg were approximately USD1.87bn, according to IQVIA.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 25, 2019
Words:185
Previous Article:AbbVie partners with Voyager to develop and commercialise vectorized antibodies for Parkinson's disease and other diseases.
Next Article:Phoenix Tissue Repair treats first patient in Phase 1/2 clinical trial of PTR-01 for RDEB.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters